We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents (HGG-CilMetro)

This study has been terminated.
(due to an altered benefit/risk assessment.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01517776
First Posted: January 25, 2012
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Merck KGaA
Information provided by (Responsible Party):
Christof Kramm, Martin-Luther-Universität Halle-Wittenberg
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2014
  Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: May 26, 2015